Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deyuan Zhong

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Asian Journal of Surgery|November 9, 2024
Intraoperative electron beam radiotherapy combined with gemcitabine and PD-L1 inhibitors for unresectable pancreatic cancer: Report of 3 casesDeyuan Zhong, Yuxin Liang, Hongtao Yan, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 20, 2021
Mixed Adenoneuroendocrine Carcinoma of the GallbladderZilong Zhang, Deyuan Zhong, Tianhang Feng, et al.
Oncology Letters|May 8, 2026
Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with vascular invasion: A systematic review and meta-analysisYuhao Su, Yuxin Liang, Deyuan Zhong, et al.
Journal of Hepatocellular Carcinoma|June 22, 2026
Tumor-Associated Macrophages in Hepatocellular Carcinoma: From Ontogeny and Heterogeneity to Immune Evasion and Therapeutic TargetingYuhao Su, Yuxin Liang, Deyuan Zhong, et al.
Technology in Cancer Research & Treatment|February 5, 2026
Prognostic Value of the Ratio of Interleukin-2 and Interleukin-10 in Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 TherapyDeyuan Zhong, Yuxin Liang, Yuhao Su, et al.
Frontiers in Immunology|September 12, 2025
Efficacy and safety of postoperative adjuvant HAIC combining lenvatinib with or without PD-1 inhibitors in solitary large HCC: A multicenter retrospective studyYuxin Liang, Ming Wang, Deyuan Zhong, et al.
BMC Cancer|March 7, 2025
Efficacy and safety of postoperative adjuvant HAIC with FOLFOX combining PD-1 inhibitors in HCC patients with microvascular invasion: a propensity score matching analysisYuxin Liang, Deyuan Zhong, Jin Shang, et al.
BMC Cancer|March 20, 2025
Construction and validation of a novel liver function-tumor burden-inflammation-nutrition (LTIN) score for HCC patients underwent hepatectomyYuhao Su, Yuxin Liang, Deyuan Zhong, et al.
Frontiers in Immunology|May 8, 2026
TACE plus lenvatinib and envafolimab for conversion therapy in unresectable HCC: a prospective pilot studyYuhao Su, Yuxin Liang, Deyuan Zhong, et al.
Journal of Translational Medicine|June 19, 2026
S-propargyl-cysteine remodels the HCC microenvironment and potentiates anti-PD-1 therapy through CSE/H<sub>2</sub>S-linked vascular and immune reprogrammingYuxin Liang, Deyuan Zhong, Hongtao Yan, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Asian Journal of Surgery|November 9, 2024
Intraoperative electron beam radiotherapy combined with gemcitabine and PD-L1 inhibitors for unresectable pancreatic cancer: Report of 3 casesDeyuan Zhong, Yuxin Liang, Hongtao Yan, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 20, 2021
Mixed Adenoneuroendocrine Carcinoma of the GallbladderZilong Zhang, Deyuan Zhong, Tianhang Feng, et al.
Oncology Letters|May 8, 2026
Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with vascular invasion: A systematic review and meta-analysisYuhao Su, Yuxin Liang, Deyuan Zhong, et al.
Journal of Hepatocellular Carcinoma|June 22, 2026
Tumor-Associated Macrophages in Hepatocellular Carcinoma: From Ontogeny and Heterogeneity to Immune Evasion and Therapeutic TargetingYuhao Su, Yuxin Liang, Deyuan Zhong, et al.
Technology in Cancer Research & Treatment|February 5, 2026
Prognostic Value of the Ratio of Interleukin-2 and Interleukin-10 in Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 TherapyDeyuan Zhong, Yuxin Liang, Yuhao Su, et al.
Frontiers in Immunology|September 12, 2025
Efficacy and safety of postoperative adjuvant HAIC combining lenvatinib with or without PD-1 inhibitors in solitary large HCC: A multicenter retrospective studyYuxin Liang, Ming Wang, Deyuan Zhong, et al.
BMC Cancer|March 7, 2025
Efficacy and safety of postoperative adjuvant HAIC with FOLFOX combining PD-1 inhibitors in HCC patients with microvascular invasion: a propensity score matching analysisYuxin Liang, Deyuan Zhong, Jin Shang, et al.
BMC Cancer|March 20, 2025
Construction and validation of a novel liver function-tumor burden-inflammation-nutrition (LTIN) score for HCC patients underwent hepatectomyYuhao Su, Yuxin Liang, Deyuan Zhong, et al.
Frontiers in Immunology|May 8, 2026
TACE plus lenvatinib and envafolimab for conversion therapy in unresectable HCC: a prospective pilot studyYuhao Su, Yuxin Liang, Deyuan Zhong, et al.
Journal of Translational Medicine|June 19, 2026
S-propargyl-cysteine remodels the HCC microenvironment and potentiates anti-PD-1 therapy through CSE/H<sub>2</sub>S-linked vascular and immune reprogrammingYuxin Liang, Deyuan Zhong, Hongtao Yan, et al.
Pageof 4